Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
Bringing End-to-End Spatial Biology Solutions to Life Sciences Researchers for Advanced Spatial Proteomics Analysis
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319615932/en/
Akoya offers a comprehensive suite of high-throughput automated multiplex immunofluorescence platforms, reagents, and ready-to-use PhenoCode™ panels. Akoya’s PhenoCycler®-Fusion and PhenoImager® HT platforms are at the forefront of spatial biology and offer significant advancements in speed and scale for high-parameter tissue analysis.
As a qualified CRO of Akoya, BostonGene will perform multiplex immunofluorescence and analysis using Akoya's high-plex PhenoCycler®-Fusion and PhenoImager® HT whole slide imaging platforms, harmonizing wet lab processing with advanced bioinformatics providing end-to-end imaging solutions for life sciences researchers, advancing the understanding of complex biological processes and supporting the development of personalized therapies.
“With our PhenoCycler®-Fusion and PhenoImager® HT platforms, BostonGene can offer spatial phenotyping services to enable the acceleration of immunotherapy discovery and development in biopharma and academic settings,” said
“We look forward to leveraging Akoya’s solutions for streamlined high-throughput multiplex immunofluorescence experiments,” said
About
BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s testsreveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.
About
As
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319615932/en/
Media Contact:
BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com
Source: BostonGene